title: Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum.
abstract: The psychomotor stimulant methamphetamine (METH) has been shown to cause specific behaviors such as hyperlocomotion in rodents. Pretreatment of repeated s.c. administration of clorgyline (1 mg/kg, once per day for 5 consecutive days), a monoamine oxidase (MAO)-A inhibitor, blocked hyperlocomotion induced by a single i.p. administration of METH (1 mg/kg) in male ICR mice, without any effect on spontaneous locomotion. The blockade was also observed when mice were pretreated with a single administration of clorgyline (1 mg/kg, s.c.), without potentiating hyperlocomotion and rearing induced by a single challenge of METH at the range of 0.5-2 mg/kg (i.p.). In contrast, single or repeated pretreatment of selegiline (0.3 mg/kg, s.c.), a MAO-B inhibitor, had no effect on METH-induced hyperlocomotion. Clorgyline pretreatment, both single and repeated, altered the effects of single METH challenges on apparent 5-hydroxytryptamine (serotonin) turnover in the region of the striatum and accumbens. These results suggest that clorgyline tends to oppose METH-induced hyperlocomotion through alteration of the serotonergic system in the region of the striatum and accumbens.
authors.affiliation: Department of Pharmacology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kitanaka
authors.forename: J
authors.initials: J
authors.lastname: Kitanaka
authors.forename: M
authors.initials: M
authors.lastname: Takemura
mesh_terms: D000818:Animals; D003010:Clorgyline / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006948:Hyperkinesis / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008694:Methamphetamine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D051379:Mice; D008813:Mice, Inbred ICR; D008995:Monoamine Oxidase / Q000187:drug effects / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D012642:Selegiline / Q000494:pharmacology; D012701:Serotonin / Q000378:metabolism*
chemical_list: D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D012701:Serotonin; D008694:Methamphetamine; D008995:Monoamine Oxidase; D003010:Clorgyline